Drug discovery

#Cell line development #Cell lines #Drug discovery #Interview

Addressing the growing demand for new treatments with cell lines

Dr James Taylor, Senior Scientist in Cell Line Development at Samsung Biologics, speaks with DDW’s Megan Thomas about how to address the challenges in meeting complex molecule requirements, regulatory standards, and environmental sustainability. Benefits for developers  The biopharmaceutical industry has seen a surge in demand for drugs that treat… Read More

#Exclusive Content

AI and genomics
#Artificial intelligence (AI) #Drug discovery #Generative AI

New generative AI tool halves research time, data​ suggests

​​Elsevier has launched ScienceDirect AI, a generative AI tool for researchers. It is designed to transform the way researchers work by enabling them to instantly extract, summarise and compare trusted insights from millions of full-text articles and book chapters on ScienceDirect, a platform for peer-reviewed research. Researchers engage with a… Read More

#News

Monoclonal antibodies
#Antibodies #Biotechnology #Collaboration #Drug development #Drug discovery #Pierre Fabre Laboratories #RedRidge

Pharma/biotech biparatopic antibody collaboration agreed

Pierre Fabre Laboratories and RedRidge have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories’ innovation strategy, the partnership’s therapeutic focus will be on precision oncology as well as dermatology and rare diseases. Read More

#News

#Antibody drug conjugate (ADC) #Big pharma #Drug development #Drug discovery #Heidelberg Pharma #Takeda #Therapeutic Antibodies

A global overview of therapeutic antibody development

DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More

#Business & Investment #Exclusive Content

#Artificial intelligence (AI) #Data automation #Drug discovery #Laboratory data #Webinar

Webinar: Implement a successful data automation strategy

The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More

Webinar date:
Supported by Benchling
#News

#Artificial intelligence (AI) #Drug discovery #Molecular research #Ozempic #Stanford University #Weight loss

AI-enabled molecule discovery rivals Ozempic in weight loss

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic — in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of Ozempic’s side effects such as nausea, constipation and significant loss of muscle… Read More

#News

#Drug discovery #Protein chemistry / Proteomics #Protein engineering #Synthetic biology #Synthetic DNA #Webinar

Register now: Synthesised DNA for protein screening

A new webinar is now open for registration entitled ‘Using ENFINIA cell-free synthesised DNA for rapid protein expression and screening in the myTXTL cell-free system‘. Cell-free transcription-translation (TXTL) systems can be used for rapid and flexible protein expression and screening workflows, powering protein engineering and discovery, synthetic biology, AI-driven… Read More

Webinar date:
Supported by Elegen Bio
#News

#2025 predictions #Drug development #Drug discovery #Regulatory

New modalities: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience, cancer research, cell and gene therapy, diagnostics and regulation and drug policy. This is the final… Read More

#Exclusive Content #Regulatory #Trends & Analysis

#Business #Drug development #Drug discovery #Spinout #Start-ups #Turning Science into Business

New DDW Highlights podcast: 10 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are… Read More

#News

Red blood cells
#Assays #Cellular imaging #Drug discovery #High throughput screening #In vitro #Technical Note

Technical Note: Unlocking high-throughput potential

A new Technical Note from Lonza is now available entitled ‘Primary Human Umbilical Vein Endothelial Cells: A Qualitative, Real-time, In-vitro Tube Formation Assay‘. Download the Technical Note to learn more about these unique features: Co-culture model with high biological relevance Compatible with live-cell imaging which allows for real-time… Read More

#News

#Acute pancreatitis #Arrivo BioVentures #Drug discovery #Major depressive disorder #Meet the Researcher

Meet the researcher: Greg Rigdon, Arrivo BioVentures

DDW’s Megan Thomas looks at a day in the life of Greg Rigdon, Senior Vice President of Scientific Affairs at Arrivo BioVentures. MT: Can you tell us what you do and what you’re working on at the moment? GR: My Arrivo colleagues and I are working on two potentially breakthrough… Read More

#Exclusive Content

#Business #Drug development #Drug discovery #Spinout #Start-ups #Turning Science into Business

This week in drug discovery (3-7 March) 

News round-up for 3-7 March by DDW Senior Digital Content Editor Diana Spencer. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are coming through and sparking new life into various areas of drug discovery. The top stories: Start-up… Read More

#News

Robot for drug discovery
#Artificial intelligence (AI) #Automation / robotics #Drug discovery #Insilico Medicine #Lab automation #Lab technology

First bipedal humanoid AI scientist joins drug discovery lab

Insilico Medicine has deployed the first bipedal humanoid in its AI-powered fully-robotic drug discovery laboratory.   The humanoid, called ‘Supervisor’, will be used for data acquisition and data generation for training of the embodied AI systems to learn the skills of human laboratory scientists.   The work… Read More

#News #Trending News